FOREIGN PATENT DOCUMENTS Date Country Class Subclass Translation Yes No.				T			Sheet <u>1 of 1</u> .
BY APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMENTS Examinor Initial Document Number Date Name Class Subclass Filing Date If Appropriate	Form PTO-144						
U.S. PATENT DOCUMENTS Subclass Filing Date Name Class Subclass Filing Date If Appropriate	INFORM	ATION DISCLOSUR	RE STATEMENT				
U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Document Number Date Name Class Subclass Filing Date Page P		BY APPLICAN	IT	· ·			
Document Number Date Name Class Subclass Filing Date If Appropriate	•	(Use several sheets if no					
Document Number Date Name Class Subclass Filing Date If Appropriate			U.S. PATENT	DOCUMENTS			
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010	Examiner Initial	Document Number			Class	Subclass	
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
Document Number Date Country Class Subclass Translation Yes No. No. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER /Danah Al-awadi/ DATE CONSIDERED 08/16/2010 DATE CONSIDERED 08/16/2010							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include convol this form with next communication to applicant							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		Document Number	Date	Country	Class	Subclass	
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		OTHER DO	CUMENTS (Including A)	uthor Title Date Pertinen	l Pages F		
Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include convot this form with next communication to applicant.							s) and
and NDA 21-202/S-016. Pages 3-32. (August 27, 2008) EXAMINER Danah Al-awadi/ Date Considered D	/D.A./						
/Danah Al-awadi/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant							
/Danah Al-awadi/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant							
/Danah Al-awadi/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant							
/Danah Al-awadi/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant							
/Danah Al-awadi/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant							
in conformance and not considered. Include copyof this form with next communication to applicant	EXAMINER		vadi/	DATE CONSIDERED		08/16/2010	<u> </u>
n:\kls\cases\pb60432\pb60432_us_supp_pto1449_10567803.doc	in conformance	and not considered. Inc	lude copyof this form with			raw line throug	h citation if not